BR0014895A - Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais - Google Patents
Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinaisInfo
- Publication number
- BR0014895A BR0014895A BR0014895-4A BR0014895A BR0014895A BR 0014895 A BR0014895 A BR 0014895A BR 0014895 A BR0014895 A BR 0014895A BR 0014895 A BR0014895 A BR 0014895A
- Authority
- BR
- Brazil
- Prior art keywords
- sodium
- polyethylene glycol
- potassium salt
- atpase inhibitor
- gastrointestinal diseases
- Prior art date
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title abstract 5
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 4
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title abstract 4
- 229910052708 sodium Inorganic materials 0.000 title abstract 4
- 239000011734 sodium Substances 0.000 title abstract 4
- 229940121819 ATPase inhibitor Drugs 0.000 title abstract 3
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 abstract 3
- 239000012669 liquid formulation Substances 0.000 abstract 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903831A SE9903831D0 (sv) | 1999-10-22 | 1999-10-22 | Formulation of substituted benzimidazoles |
| PCT/SE2000/001992 WO2001028558A1 (en) | 1999-10-22 | 2000-10-13 | Formulation of substituted benzimidazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0014895A true BR0014895A (pt) | 2002-06-18 |
Family
ID=20417464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0014895-4A BR0014895A (pt) | 1999-10-22 | 2000-10-13 | Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais |
Country Status (35)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001276721A1 (en) * | 2000-08-04 | 2002-02-18 | Takeda Chemical Industries Ltd. | Salts of benzimidazole compound and use thereof |
| WO2002015908A1 (en) * | 2000-08-18 | 2002-02-28 | Takeda Chemical Industries, Ltd. | Injections |
| MY137726A (en) * | 2000-11-22 | 2009-03-31 | Nycomed Gmbh | Freeze-dried pantoprazole preparation and pantoprazole injection |
| GB2376231A (en) * | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
| MXPA04002973A (es) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosis de liberacion modificada. |
| FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
| FR2845916B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |
| FR2845917B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
| FR2848555B1 (fr) | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
| CN100558726C (zh) * | 2003-02-24 | 2009-11-11 | 田边三菱制药株式会社 | 泰妥拉唑的对映体及其在治疗中的应用 |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| US20060089376A1 (en) * | 2004-10-27 | 2006-04-27 | Joshi Ramesh A | Tenatoprazole salts and process of preparation thereof |
| AU2007248949B2 (en) * | 2006-05-09 | 2010-04-08 | Astrazeneca Ab | Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation |
| CN100411613C (zh) * | 2006-12-08 | 2008-08-20 | 中国药科大学 | 一种奥美拉唑速释固体制剂及其制备方法 |
| JP6698651B2 (ja) | 2014-11-13 | 2020-05-27 | スリーエム イノベイティブ プロパティズ カンパニー | 試料中の細菌ａｔｐを検出するためのａｔｐ−ジホスホヒドロラーゼを含むキット |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2025078989A1 (en) * | 2023-10-11 | 2025-04-17 | Reena Patel | Stabilized pharmaceutical compositions |
| WO2025181379A1 (en) * | 2024-03-01 | 2025-09-04 | Etico Lifesciences Private Limited | Liquid, storage stable, directly injectable, pantoprazole formulations, their uses and manufacturing |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| DK399389A (da) | 1988-08-18 | 1990-02-19 | Takeda Chemical Industries Ltd | Injicerbare oploesninger |
| JP2536173B2 (ja) * | 1988-08-18 | 1996-09-18 | 武田薬品工業株式会社 | 注射剤 |
| KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
| SG52479A1 (en) | 1992-07-28 | 1998-09-28 | Astra Ab | Injection and injection kit containing omeprazole and its analogs |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| TW359614B (en) | 1993-08-31 | 1999-06-01 | Takeda Chemical Industries Ltd | Composition containing benzimidazole compounds for rectal administration |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US5877205A (en) | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
-
1999
- 1999-10-22 SE SE9903831A patent/SE9903831D0/xx unknown
-
2000
- 2000-10-06 AR ARP000105283A patent/AR029005A1/es unknown
- 2000-10-09 TW TW089121063A patent/TWI236372B/zh not_active IP Right Cessation
- 2000-10-13 SK SK539-2002A patent/SK286266B6/sk not_active IP Right Cessation
- 2000-10-13 DE DE60022789T patent/DE60022789T2/de not_active Expired - Lifetime
- 2000-10-13 ES ES00973295T patent/ES2246903T3/es not_active Expired - Lifetime
- 2000-10-13 NZ NZ518155A patent/NZ518155A/en unknown
- 2000-10-13 SI SI200030759T patent/SI1274427T1/sl unknown
- 2000-10-13 AU AU11823/01A patent/AU782866B2/en not_active Ceased
- 2000-10-13 PL PL354926A patent/PL199868B1/pl not_active IP Right Cessation
- 2000-10-13 CA CA2425199A patent/CA2425199C/en not_active Expired - Fee Related
- 2000-10-13 CZ CZ20021375A patent/CZ20021375A3/cs unknown
- 2000-10-13 CN CNB008146373A patent/CN1213751C/zh not_active Expired - Fee Related
- 2000-10-13 MX MXPA02003900A patent/MXPA02003900A/es active IP Right Grant
- 2000-10-13 US US09/701,714 patent/US6730685B1/en not_active Expired - Fee Related
- 2000-10-13 BR BR0014895-4A patent/BR0014895A/pt not_active IP Right Cessation
- 2000-10-13 AT AT00973295T patent/ATE304851T1/de active
- 2000-10-13 DK DK00973295T patent/DK1274427T3/da active
- 2000-10-13 EP EP00973295A patent/EP1274427B1/en not_active Expired - Lifetime
- 2000-10-13 UA UA2002043345A patent/UA74347C2/uk unknown
- 2000-10-13 IL IL14910700A patent/IL149107A0/xx active IP Right Grant
- 2000-10-13 TR TR2002/01103T patent/TR200201103T2/xx unknown
- 2000-10-13 EE EEP200200204A patent/EE05175B1/xx not_active IP Right Cessation
- 2000-10-13 JP JP2001531388A patent/JP2003512327A/ja active Pending
- 2000-10-13 HU HU0203121A patent/HUP0203121A3/hu unknown
- 2000-10-13 RU RU2002110328/15A patent/RU2286782C2/ru not_active IP Right Cessation
- 2000-10-13 KR KR1020027005112A patent/KR100785603B1/ko not_active Expired - Fee Related
- 2000-10-13 WO PCT/SE2000/001992 patent/WO2001028558A1/en not_active Ceased
- 2000-10-19 CO CO00079671A patent/CO5261533A1/es active IP Right Grant
- 2000-10-19 MY MYPI20004932A patent/MY131971A/en unknown
-
2002
- 2002-04-10 BG BG106602A patent/BG65580B1/bg unknown
- 2002-04-11 IL IL149107A patent/IL149107A/en not_active IP Right Cessation
- 2002-04-12 ZA ZA200202905A patent/ZA200202905B/en unknown
- 2002-04-17 IS IS6347A patent/IS2196B/is unknown
- 2002-04-19 NO NO20021860A patent/NO329545B1/no not_active IP Right Cessation
-
2005
- 2005-12-19 CY CY20051101567T patent/CY1106055T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU95102778A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен | |
| DE69616749D1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
| PA8452201A1 (es) | Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos. | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| BR9910849A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido. | |
| NO974163D0 (no) | Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi | |
| BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| MD960307A (ro) | Compoziţii farmaceutice cu conţinut de acid hialuronic, utilizarea compoziţiilor pentru tratamentul bolilor pielii, metodă de tratament al bolilor pielii | |
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| PE20050822A1 (es) | Derivados de florfenicol con mejor solubilidad en agua | |
| BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
| DK360187D0 (da) | Diphenylpropylaminderivater, deres fremstilling og anvendelse | |
| CY1106055T1 (el) | Τυποποιηση των υποκατεστημενων βενζιμιδαζολων | |
| ES2087623T3 (es) | Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon. | |
| ES2147629T3 (es) | Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene. | |
| FI102964B1 (fi) | Terapeuttisia yhdisteitä | |
| AR005860A1 (es) | Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen, y su utilización. | |
| CN101522692A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| WO2002064552A8 (en) | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | |
| BRPI0409387A (pt) | método para o tratamento de doença de tecido mole em um indivìduo mamìfero, composição farmacêutica, complexo de alvejamento de tecido mole, método para a formação de um complexo, e, kit para uso em um método | |
| GT199900171A (es) | Concentrado oral de sertralina. | |
| ATE333897T1 (de) | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen | |
| DK1332764T3 (da) | Mucoadhæsivt, termoresponsivt lægemiddel-bærer-præparat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: A61K 31/44, A61K 47/30 Ipc: A61K 9/08 (2010.01), A61K 31/44 (2010.01), A61K 47 |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014. |